EMCURE

Emcure Pharmaceuticals Share Price

₹1,098.80 +90.5 (8.98%)

19 Apr, 2025 11:17

SIP TrendupStart SIP in EMCURE

Start SIP

Performance

  • Low
  • ₹1,009
  • High
  • ₹1,109
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,580
  • Open Price₹1,011
  • Previous Close₹1,008
  • Volume529,139

Investment Returns

  • Over 1 Month + 17.2%
  • Over 3 Month -19.32%
  • Over 6 Month -26.44%
  • Over 1 Year + 9.01%
SIP Lightning

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.3
  • PEG Ratio
  • -
  • Market Cap Cr
  • 20,820
  • P/B Ratio
  • 5.1
  • Average True Range
  • 62.09
  • EPS
  • 32.07
  • Dividend Yield
  • 0
  • MACD Signal
  • -15.56
  • RSI
  • 61.48
  • MFI
  • 84.95

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,098.80
+ 90.5 (8.98%)
pointer
  • stock-down_img
  • Bearish Moving Average 3
  • stock-up_img
  • Bullish Moving Average 11
  • 20 Day
  • ₹996.97
  • 50 Day
  • ₹1,050.98
  • 100 Day
  • ₹1,144.04
  • 200 Day
  • -

Resistance and Support

1072.13 Pivot Speed
  • R3 1,236.37
  • R2 1,172.73
  • R1 1,135.77
  • S1 1,035.17
  • S2 971.53
  • S3 934.57

What's your outlook on Emcure Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 7,551.11 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 16% is good. The company has a reasonable debt to equity of 26%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 7% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 110 indicates it belongs to a poor industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-06 Quarterly Results
2024-11-07 Quarterly Results
2024-08-13 Quarterly Results

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.94%
3.1%
0.36%
3.05%
5.14%
10.41%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,098 As on 19 April, 2025 | 11:03

The Market Cap of Emcure Pharmaceuticals is ₹20820.4 Cr As on 19 April, 2025 | 11:03

The P/E ratio of Emcure Pharmaceuticals is 34.3 As on 19 April, 2025 | 11:03

The PB ratio of Emcure Pharmaceuticals is 5.1 As on 19 April, 2025 | 11:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23